Stem Cell Therapy Market to Witness Growth Acceleration During 2020-2025 – Aerospace Journal

The latest Stem Cell Therapy market research added by Market Study Report, LLC, delivers a concise outline regarding the potential factors likely to drive the revenue growth of this industry. The report delivers valuable insights on market revenue, SWOT Analysis, market share, profit estimation and regional landscape of this business vertical. Moreover, the report focuses on significant growth factors and obstacles accepted by market leaders in the Stem Cell Therapy market.

The Stem Cell Therapy market report offers a comprehensive analysis of this industry vertical, emphasizing on the key growth stimulants, opportunities, and constraints projected to shape the market dynamics over the forecast period.

Request a sample Report of Stem Cell Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2422751?utm_source=aerospace-journal.com&utm_medium=AG

As per industry experts, the market is anticipated to grow significantly, registering a CAGR of XX% over the analysis period of 2020-2025.

Instabilities in the supply & demand channels due to the stringent lockdown measures imposed to address the COVID-19 pandemic has left numerous companies in disarray. Speaking of the ambiguity of revenues in the near term, businesses are expected to face hindrance even once the economy recovers from the pandemic.

Additionally, the report offers a holistic assessment of various industry segments to infer the revenue projections for the market over the study duration.

Key inclusions of the Stem Cell Therapy market report:

Ask for Discount on Stem Cell Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2422751?utm_source=aerospace-journal.com&utm_medium=AG

Comprehensive assessment of all opportunities and risks in the Stem Cell Therapy market.

Stem Cell Therapy Market segments covered in the report:

Product spectrum:

Applications spectrum:

Regional analysis: North America, Europe, Asia-Pacific, South America, Middle East and Africa

Competitive landscape:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-stem-cell-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

Some of the Major Highlights of TOC covers:

Executive Summary

Manufacturing Cost Structure Analysis

Development and Manufacturing Plants Analysis of Stem Cell Therapy

Key Figures of Major Manufacturers

Related Reports:

1. Global Natural Killer Cell Therapy Market 2020 by Company, Regions, Type and Application, Forecast to 2025 This report includes the assessment of Natural Killer Cell Therapy market size for value and volume. Both top-down and bottom-up approaches have been used to estimate and validate the Natural Killer Cell Therapy market, to estimate the size of various other dependent submarkets in the overall market. Read More: https://www.marketstudyreport.com/reports/global-natural-killer-cell-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

2. Global Allergen Blocker Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 Allergen Blocker Market report characterize imperative Portion and contenders of the market regarding market estimate, volume, esteem. This report likewise covers every one of the locales and nations of the world, which demonstrates a territorial improvement status, it additionally incorporates Business Profile, Introduction, Revenue and so on. Read More: https://www.marketstudyreport.com/reports/global-allergen-blocker-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2025

Read More Reports On: https://www.marketwatch.com/press-release/Unified-Network-Management-Market-Size-Technological-Advancement-and-Growth-Analysis-with-Forecast-to-2025-2020-10-26

Contact Us: Corporate Sales, Market Study Report LLC Phone: 1-302-273-0910 Toll Free: 1-866-764-2150 Email: [emailprotected]

Read more:
Stem Cell Therapy Market to Witness Growth Acceleration During 2020-2025 - Aerospace Journal

Bayer to pay $2B upfront for AskBio to drive gene therapy expansion – FierceBiotech

Bayer has struck a deal to acquire Asklepios BioPharmaceutical for $2 billion upfront. The deal, which features an additional $2 billion in milestones, will give Bayer control of an adeno-associated virus (AAV) gene therapy platform and a pipeline led by clinical-phase treatments for Parkinsons, Pompe disease and congestive heart failure.

Asklepios, known as AskBio, is a veteran of the gene therapy space. Jude Samulski, a pioneer of AAV vectors, founded the company in 2001. Since then, AskBio has built out an AAV platform and an associated high-yield cell line, and it's worked with Columbus Venture Partners to establish gene therapy manufacturing capacitya scarce, valuable resource in the booming industry. The manufacturing site is run by Viralgen, the CDMO AskBio set up with Columbus.

AskBio, which provided the self-complementary DNA technology used in Novartis approved gene therapy Zolgensma, has used its capabilities to develop an internal pipeline of neuromuscular, central nervous system, cardiovascular and metabolic gene therapies.

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

Germanys Bayer has valued the assets at $2 billion upfront, plus the same again in success-based milestones. Three-quarters of the success-based milestones are tied to events scheduled to happen in the next five years.

Bayer sees potential to use AskBios platform to tackle relatively large, polygenetic indications. The company also foresees opportunities to use the CDMO business as the foundation for partnerships involving AAV therapies.

Once the deal closes, likely in the fourth quarter, Bayer will allow AskBio to operate autonomously as part of a new cell and gene therapy unit in a bid to preserve its entrepreneurial culture. The cell and gene therapy unit will bundle Bayer's activities in this area moving forward in order to establish an innovation ecosystem for the participating partners, the German company said.

Bayer has begun to build out that ecosystem in recent years. Last year, Bayer paid $240 million upfront to acquire the almost 60% of BlueRock Therapeutics that it didnt already own, giving it access to an induced pluripotent stem cell (iPSC) platform and associated pipeline. Shortly before that, Bayer invested $215 million in Century Therapeutics, another iPSC startup.

The series of deals has given Bayer full or partial stakes in a clutch of cell and gene therapy programs, plus infrastructure to develop and manufacture the assets. Other companies have embarked on similar strategies, notably in the gene therapy space, leading to a series of deals that have given companies including Biogen, Novartis and Roche control of therapeutic assets and infrastructure.

View original post here:
Bayer to pay $2B upfront for AskBio to drive gene therapy expansion - FierceBiotech

Animal Stem Cell Therapy Market Analysis 2019 Growth by Top Companies and Trends by Types, Treatment, Diagnosis and Application Forecast Analysis to…

Global Animal Stem Cell Therapy Market research report presents a comprehensive overview of market size, share, evolution, trends, and forecast, and growth opportunities of Animal Stem Cell Therapy market by product type, application, key manufacturers and key regions and countries. This report offers comprehensive analysis on global Animal Stem Cell Therapy market along with, market trends, drivers, and restraints of the Animal Stem Cell Therapy market. In-depth study of market size with data Tables, Bar & Pie Charts, and Graphs & Statistics which helps easy to understand detailed breakdown of market.

Note: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2638488&source=atm

Segment by Type, the Animal Stem Cell Therapy market is segmented into Dogs Horses Others

Segment by Application, the Animal Stem Cell Therapy market is segmented into Veterinary Hospitals Research Organizations

Regional and Country-level Analysis The Animal Stem Cell Therapy market is analysed and market size information is provided by regions (countries). The key regions covered in the Animal Stem Cell Therapy market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc. The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026. Competitive Landscape and Animal Stem Cell Therapy Market Share Analysis Animal Stem Cell Therapy market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Animal Stem Cell Therapy business, the date to enter into the Animal Stem Cell Therapy market, Animal Stem Cell Therapy product introduction, recent developments, etc. The major vendors covered: Medivet Biologics LLC VETSTEM BIOPHARMA J-ARM U.S. Stem Cell, Inc VetCell Therapeutics Celavet Inc. Magellan Stem Cells Kintaro Cells Power Animal Stem Care Animal Cell Therapies Cell Therapy Sciences Animacel

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2638488&source=atm

This detailed report on Animal Stem Cell Therapy market largely focuses on prominent facets such as product portfolio, payment channels, service offerings, applications, in addition to technological sophistication. The report lends versatile cues on market size and growth traits, besides also offering an in-depth section on opportunity mapping as well as barrier analysis, thus encouraging report readers to incur growth in global Animal Stem Cell Therapy market.

This comprehensive research- documentary on global Animal Stem Cell Therapy market is a holistic perspective of market developments, factors, dynamics, trends and challenges that decide growth trajectory of global Animal Stem Cell Therapy market.

Apart from highlighting these vital realms, the report also includes critical understanding on notable developments and growth estimation across regions at a global context in this report on Animal Stem Cell Therapy market.

These leading players are analyzed at length, complete with their product portfolio and company profiles to decipher crucial market findings. Additionally, the competitive landscape of the Animal Stem Cell Therapy market is also evaluated at length in the report, to identify and analyze leading service providers.

Geographically, the detailed analysis of consumption, revenue, Animal Stem Cell Therapy market share and growth rate, historic and forecast (2015-2026) of the following regions are covered-

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

All the notable Animal Stem Cell Therapy market specific dimensions are studied and analyzed at length in the report to arrive at conclusive insights. Further, a dedicated section on regional overview of the Animal Stem Cell Therapy market is also included in the report to identify lucrative growth hubs.

This Animal Stem Cell Therapy market also harps on competition intensity, thoroughly identifying and evaluating leading players in the Animal Stem Cell Therapy market and their growth stimulators. Besides these aforementioned factors and attributes of the Animal Stem Cell Therapy market, this report specifically decodes notable findings and concludes on innumerable factors and growth stimulating decisions that make this Animal Stem Cell Therapy market a highly profitable.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2638488&licType=S&source=atm

A thorough take on essential elements such as drivers, threats, challenges, opportunities are thoroughly assessed and analyzed to arrive at logical conclusions. As the report proceeds further, Even further in the report emphasis has been lent on current, historical, as well as future growth tendencies to make accurate growth estimations based on market size, value, volume, demand and supply trends as well as growth rate.

Other vital factors related to the Animal Stem Cell Therapy market such as scope, growth potential, profitability, and structural break-down have been innately roped in this Animal Stem Cell Therapy report to accelerate market growth. This research compilation on Animal Stem Cell Therapy market is a meticulous compilation of in-depth primary and secondary research. The report also lists ample understanding on various analytical practices such as SWOT and PESTEL analysis to guide optimum profits in Animal Stem Cell Therapy market. The report is a conscious attempt to unearth market specific developments to ignite growth specific market discretion.

For More Information Kindly Contact:

marketresearchhub

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Read the original post:
Animal Stem Cell Therapy Market Analysis 2019 Growth by Top Companies and Trends by Types, Treatment, Diagnosis and Application Forecast Analysis to...

Conventional Chemotherapy May Be Effective in Early-Stage Hodgkin Lymphoma After Relapse – Cancer Therapy Advisor

Among patients with early-stage, favorable Hodgkin lymphoma (ES-HL), relapse is most common more than 12 months after initial diagnosis. For this reason, treatment regimens with conventional chemotherapy may be effective in a subset of patients after relapse, according to study results published in the Journal of Clinical Oncology.

Most patients with ES-HL have a good prognosis, with risk-adapted frontline treatments yielding a high rate of response. However, there is limited understanding of the characteristics of patients that relapse with contemporary treatments, as well as the period at which relapse is the most likely.

In addition, optimal treatment at relapse, whether a standard chemotherapy regimen such as bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) or high-dose chemotherapy followed by autologous stem cell transplantation (ASCT), has not yet been established.

For this study, researchers evaluated data from the German Hodgkin Study Group trials, HD10 (ClinicalTrials.gov Identifier: NCT00265018) and HD13 (ISRCTN registry Identifier: ISRCTN63474366), to determine characteristics at relapse, as well as treatment patterns and survival outcomes thereafter, among patients with ES-HL who had reached complete remission.

Among more than 2500 patients who partook in HD10 and HD13, the researchers identified 174 patients who reached complete remission and subsequently experienced relapse. Relapse mostly occurred more than 12 months after initial diagnosis and among those with stage I to II disease.

A total of 85 patients (49%) who experienced a relapse received a conventional chemotherapy regimen, 68% of which were BEACOPP regimens; 70 patients (41%) received ASCT, 11 patients (6%) received radiotherapy, and 4 patients (2%) received palliative regimens.

At relapse, patients older than 60 years had a hazard ratio for shorter second progression-free survival (PFS) of 3 (P =.0029). Conventional chemotherapy regimens did not lead to a shorter second PFS period vs ASCT (hazard ratio, 0.7; P =.39).

The 2-year PFS and OS rates noted with post-relapse conventional chemotherapy were 94% and 97.2%, respectively.

Taken together, we provide a comprehensive analysis of disease and treatment characteristics for relapse after initial remission with contemporary, first-line [combined-modality treatment] of ES-HL, the authors wrote.

The authors also noted that conventional chemotherapy may constitute a reasonable therapeutic option and potential alternative to ASCT in selected patients with relapse after initial treatment of ES-HL, especially in case of contraindications to ASCT or a resource-constrained setting precluding such intensified approaches.

Disclosures: Some authors have declared affiliations with or received funding from the pharmaceutical industry. Please refer to the original study for a full list of disclosures.

Brckelmann PJ, Mller H, Guhl T, et al. Relapse after early-stage, favorable Hodgkin lymphoma: disease characteristics and outcomes with conventional or high-dose chemotherapy. J Clin Oncol. Published online October 15, 2020. doi:10.1200/JCO.20.00947

This article originally appeared on Hematology Advisor

Here is the original post:
Conventional Chemotherapy May Be Effective in Early-Stage Hodgkin Lymphoma After Relapse - Cancer Therapy Advisor

Choroideremia Treatment Market Trend & Growth by Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc – PRnews Leader

Global Choroideremia Treatment Marketis expected to grow at a steady CAGR in the forecast period of 2019-2026.Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling the market growth. Global Choroideremia Treatment Market By Treatment Type (Gene Therapy, Surgery), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Ophthalmic Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Forecast to 2026

Download exclusive PDF sample report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-choroideremia-treatment-market

Some of the major competitors currently working in the global choroideremia treatment market areBiogen, 4D Molecular Therapeutics, Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc, PIXIUM VISION, Retina Implant AG, F. Hoffmann-La Roche Ltd and others.

Market Definition:

Choroideremia is also known as choroidal sclerosis is a rare, degenerative, X-linked inherited retinal disorder characterized by progressive degeneration of the choroid, retinal pigment epithelium (RPE) and retina due to Mutations in the CHM gene. This CHM gene required to produce Rab escort protein-1 (REP-1). The condition gets its name from the distinctive sweet odor of affected infants urine and is also c, a protein that takes part in targeting vesicles (small sacs of substances) into, out of, and within cells.

According to the statistics published by U.S. Department of Health & Human Services, an estimated population of choroideremia is about 1 in 50,000-100,000 people. Presence of refined healthcare infrastructure and emerging new market are the key factors for growth of this market.

Market Drivers

Market Restraints

Segmentation:Global Choroideremia Treatment Market

By Treatment

By Route of Administration

By End Users

By Distribution Channel

ByGeography

Download Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-choroideremia-treatment-market

Key Developments in the Market:

Competitive Analysis:

Global choroideremia treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares global choroideremia treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

Order a Copy of Global Choroideremia Treatment Market Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-choroideremia-treatment-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Go here to see the original:
Choroideremia Treatment Market Trend & Growth by Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc - PRnews Leader

Precision Cancer Therapies Market Research on Precision Cancer Therapies Market 2019 and Analysis to 2025 – PRnews Leader

In 2025, the market size of the Precision Cancer Therapies Market is expected to touch million US$ xx million. The revenue registered in 2019 was US$ xx million, thus depicting a growth at a CAGR of xx% from 2019. While in China, the market size was valued at US$ xx million in the forecast base year, further projected to increase up to US$ xx million till the end of 2025, with a CAGR of xx% during forecast period.

In this report, 2019 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Precision Cancer Therapies .

This report studies the global market size of Precision Cancer Therapies , especially focusing on the key regions such as United States, European Union, China, and other geographical extents (Japan, Korea, India, and Southeast Asia).

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2814689&source=atm

This study presents the Precision Cancer Therapies market production, revenue, market share, and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. The historical data breakdown for Precision Cancer Therapies for 2014-2019 is provided in the report along with company projection for 2019 to 2025.

For top companies in United States, European Union, and China, this report investigates and analyzes the production, value, price, market share, and growth rate for the manufacturers, key data from 2019 to 2025.

segment by Type, the product can be split into Hormone Therapy Immunotherapies Targeted Therapy Monoclonal Antibody Therapy Gene Therapy

Market segment by Application, split into Hospitals Diagnostic Centers Oncology Clinics Research Institutes

Based on regional and country-level analysis, the Precision Cancer Therapies market has been segmented as follows: North America United States Canada Europe Germany France U.K. Italy Russia Nordic Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia-Pacific Latin America Mexico Brazil Middle East & Africa Turkey Saudi Arabia UAE Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Precision Cancer Therapies market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020. The key players covered in this study Abbott Laboratories Bayer HealthCare GlaxoSmithKline OncoGenex Pharmaceuticals Hospira Boehringer Ingelheim AstraZeneca Aveo Pharmaceuticals

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2814689&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1 describes Precision Cancer Therapies product/service scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2 profiles the top manufacturers of Precision Cancer Therapies market, with price, sales, revenue and global market share of Precision Cancer Therapies from 2014 2019.

Chapter 3 analyses the Precision Cancer Therapies competitive situation, sales, revenue. The global Precision Cancer Therapies market shares of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4 showcases the Precision Cancer Therapies breakdown data at the regional level, to discuss the sales, revenue and growth by regions, from 2014 to 2019.

Chapter 5, 6, 7, 8, and 9 emphasize the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2014 to 2019.

Chapter 10 and 11 explain the segments by sales under type and application, with market shares and growth rate under each category, from 2014 to 2019.

Chapter 12 depicts Precision Cancer Therapies market forecasts by region, type, and application, with sales and revenue projections, from 2019 to 2025.

Chapter 13 and 14 describe Precision Cancer Therapies sales channel, distributors, customers, research findings and conclusion, appendix, and other data sources.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2814689&licType=S&source=atm

For More Information Kindly Contact:

ResearchMoz

Mr. Rohit Bhisey,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Follow this link:
Precision Cancer Therapies Market Research on Precision Cancer Therapies Market 2019 and Analysis to 2025 - PRnews Leader

Celebrities and Astronauts to "Show up for Science" at the NYSCF Gala & Science Fair – PRNewswire

NEW YORK, Oct. 23, 2020 /PRNewswire/ --Hosted by CNN Chief Medical Correspondent Sanjay Gupta, MD and featuring appearances from world-renowned cellist Yo-Yo Ma, former New York Mayor Michael Bloomberg, Whoopi Goldberg, Martha Stewart, actors Annaleigh Ashford, Lilli Cooper, Jesse Tyler Ferguson, Santino Fontana, Victor Garber, Jane Krakowski, Kelli O'Hara, Billy Porter, Seth Rogen, and John Slattery, among others, The New York Stem Cell Foundation Research Institute's first-ever virtual gala is streaming online on the evening of October 27th. Open to the public and free for all who would like to watch, guests can register at http://www.nyscf.org/gala.

Under the theme "Show Up for Science," the program will re-imagine the Science Fair, a signature element of NYSCF's traditional gala at which guests meet and talk with NYSCF Research Institute scientists, turning it into an online experience as special celebrity guests like Garber, Krakowski, andFerguson interview scientists and learn about the latest updates and breakthroughs in stem cell research. The Gala will bring the world of the NYSCF Research Institute laboratories to life, this year in a multi-platform digital experience produced by Broadway Director Scott Ellis with Music by Tree Adams and Andrew Schuyler.

The Gala also honors the three 2020 NYSCF Stem Cell Heroes: internationally renowned architect Frank Gehry; bioethicist and patient advocate Brooke Ellison, PhD, and award-winning architect and designer David Rockwell.

The 2020 NYSCF Research Institute Gala and Science Fair experience will also include NASA astronauts Serena Aun-Chancellor, MD, PhD, and Peggy Whitson, PhD, talking about stem cell research in space and about what this can mean for stem cell research. In Garber's segment, he will talk with NYSCF Senior Vice President of Research Scott Noggle, PhD, on how stem cells can help find a cure for diabetes, while Krakowski will discuss the basics of stem cells and how they are being used to study and fight COVID-19 with NYSCF Vice President, Automation Systems & Stem Cell Biology Daniel Paull, PhD.

The program will also include Ferguson speaking with NYSCF Principal Investigator Laura Andres-Martin, PhD, about NYSCF's new cutting-edge research on women's reproductive cancers, and NYSCF scientists Howard Kim, PhD, and Cecile Terrenoire, PhD will also share an update on NYSCF's macular degeneration stem cell therapy.

The 75-minute program will focus on education about science, using entertainment as a means to help viewers understand scientific concepts. It will also feature a short performance in honor of Frank Gehry by cellist Yo-Yo Ma, and a comedy skit by Fontana and Ashford.

Frank Gehry is perhaps the world's most celebrated living architect, known for his designs of landmark buildings including the Guggenheim Museum in Bilbao, Spain; Walt Disney Concert Hall in Los Angeles; and Fondation Louis Vuitton in Paris. The Los Angeles-based architect, whose buildings are known for the sweeping shapes and dramatic silhouettes, has won the Pritzker Prize, long considered the architecture profession's equivalent of the Nobel, as well as the Praemium Imperiale in Japan and the Gold Medal of the American Institute of Architects and the Gold Medal of the Royal Institute of British Architects. Frank has also dedicated himself to philanthropic work throughout his long career with numerous pro bono design projects in the arts, and he has had a longstanding engagement with medical research. NYSCF is honored to count Frank as a steadfast supporter of its mission to accelerate better treatments and cures for the most devastating diseases of our time through stem cell research.

David Rockwell is the founder and President of the Rockwell Group, an interdisciplinary and innovative architecture and design firm based in New York with offices in Los Angeles and Madrid, with work that ranges from restaurant and hotel design to cultural and educational institutions, theaters, and stage sets, to self-initiated pro bono projects supporting New York City during times of crisis. Ten years ago, David conceptualized the first Science Fair at a NYSCF Gala, and for many years he designed the environment that simulates the NYSCF Research Institute Laboratories and allows benefit guests to meet and mingle with NYSCF scientists. He has received numerous awards and recognition for his groundbreaking work, including a Tony Award in 2016 for set design, and NYSCF is honored to recognize his dedication, creativity, and talent for making cutting-edge science come alive each fall.

Brooke Ellison, PhD, is an Associate Professor at Stony Brook University, and the Director of Education and Ethics at the Stony Brook Stem Cell Facility. An expert in stem cell research policy and ethics, and longtime patient and disability advocate, Brooke has dedicated her professional career to changing the perception of life-saving science. Paralyzed from the neck down and dependent on a ventilator since age eleven following an accident, Brook has surmounted innumerable hurdles to achieve her goals, including serving on the Empire State Stem Cell Board, which designed New York State's stem cell policy. NYSCF is proud to recognize Brooke's tireless efforts to bring the promise of stem cell research to fruition, and for her advocacy for people in need of better solutions.

"Scientific research is more important than ever, particularly now in the midst of a global pandemic," stated NYSCF Research Institute CEO and Founder Susan L. Solomon. "I am thrilled that we are able to bring our research to life through this digital medium, and to honor our three incredible stem cell heroes. Private philanthropy is the fuel that drives our scientific success, and the Gala and Science Fair celebration highlight both the importance of our work and the promise of stem cell research around the world."

About The New York Stem Cell Foundation Research Institute

The New York Stem Cell Foundation (NYSCF) Research Institute is an independent non-profit organization accelerating cures and better treatments for patients through stem cell research. The NYSCF global community includes over 190 researchers at leading institutions worldwide, including the NYSCF Druckenmiller Fellows, the NYSCF Robertson Investigators, the NYSCF Robertson Stem Cell Prize Recipients, and NYSCF Research Institute scientists and engineers. The NYSCF Research Institute is an acknowledged world leader in stem cell research and in developing pioneering stem cell technologies, including the NYSCF Global Stem Cell Array and in manufacturing stem cells for scientists around the globe. NYSCF focuses on translational research in an accelerator model designed to overcome barriers that slow discovery and replace silos with collaboration. For more information, visitwww.nyscf.org.

David McKeon 212-365-7440 [emailprotected]

SOURCE The New York Stem Cell Foundation

Home

View original post here:
Celebrities and Astronauts to "Show up for Science" at the NYSCF Gala & Science Fair - PRNewswire

Mystery Solved: How Do Tips of Plants Stay Virus-Free in Face of Intensive Infection? – SciTechDaily

WUSCHEL proteins resist the viral invasion by inhibiting the protein assembly line of the plant stem cell. Credit: LIANG Yan, CHEN Lei

Plants are able to keep growing indefinitely because they have tissues made of meristems plant stem cells which have the unique ability to transform themselves into the various specialized cells that make up the plant, dividing whenever appropriate and producing new cells of whatever type as needed. Meristems exist at the tips of all plants, allowing them to grow new stems or new roots, and, in trees, also in the trunk, where they add extra girth.

It has been known since the 1950s that the meristems at the tips of plants, or shoot apical meristems (SAM), have the remarkable ability to remain virus-free as they give birth to their specialized daughter cells, even if the rest of the plant is thoroughly infected by a virus. This happens not just for one or even a few viruses, but a very wide range of them.

This virus-beating ability in perhaps the most important part of a plant has been exploited by scientists and farmers since then in order to cultivate new plants from donor plants that are infected, but without passing on the virus. They simply snip a tiny part of the tip, raise it for a time in a test tube or petri dish, and repeat it several times, the plant cutting typically grows pathogen-free.

Researchers at the University of Science and Technology of China (USTC) have offered new insights into this incredible ability in a new study published on October 8, 2020, in Science.

Stem cells at the tips of plants have been known to keep viruses away from this region, even as an infection ravages the rest of the plant. Quite how this happens has long been something of a mystery to scientists. Until now. Researchers at the University of Science and Technology of China (USTC) have offered new insights into this incredible ability in a new study published on Oct 8th in Science. They found surprisingly that the WUSCHEL proteins worked to inhibit production of viral proteins. The researchers are interested in seeing whether this strategy can be applied in breeding to obtain broad-spectrum antiviral crop varieties in the future says Zhong Zhao, paper author and a professor from the School of Life Science at USTC. Credit: News Center of University of Science and Technology of China

The research team inoculated a thale cress plant (Arabidopsis thaliana, related to cabbage and mustard, often used in botanical research as a model organism) with Cucumber Mosaic Virus and watched what happened.

As the virus spread towards the SAM, they noticed that it halted just before it got to a region called the WUSCHEL-expression domain. Taking a very close look at the distribution of the WUSCHEL regulator proteins here, they noticed more had appeared where the virus had tried to establish itself upon inoculation. WUSCHEL is an extremely important protein that plays a key, regulating role in determining stem cell fate, at the early stages of the development of a plant embryo, and also oversees the meristems, maintaining them in an undifferentiated state and specifying what sort of daughter cells they will produce.

Then they inoculated virus directly into the cresss stem cell and just below it, and found that the virus only spread in the latter region. Theres a chemical called dexamethasone that can induce production of these WUSCHEL proteins in our tested plants, said Zhong Zhao, paper author and a professor from the School of Life Science at USTC, so next, we inoculated more cress with the virus and then gave some of the plants dexamethasone treatment, and some we just left alone. Some 89 percent of the plants without the treatment were infected with the virus, but 90 percent of those with the treatment were free from virus invasion.

How does WUSCHEL beat viruses? They found surprisingly that the WUSCHEL proteins worked to inhibit production of viral proteins.

Viruses cant make their own proteins, but rather hijack the protein assembly line of an organism and make it produce copies of the virus. The WUSCHEL proteins, which do so much to regulate the SAM, had in essence frozen all protein production whether by the plant for itself or when hijacked by the virus thus preventing the viruses from replicating.

Genes similar to those that direct production of WUSCHEL proteins in the thale cress are very widespread across the plant kingdom, so the researchers are interested in seeing whether this strategy can be applied in breeding to obtain broad-spectrum antiviral crop varieties in the future says Zhao.

Reference: WUSCHEL triggers innate antiviral immunity in plant stem cells by Haijun Wu, Xiaoya Qu, Zhicheng Dong, Linjie Luo, Chen Shao, Joachim Forner, Jan U. Lohmann, Meng Su, Mengchu Xu, Xiaobin Liu, Lei Zhu, Jian Zeng, Sumei Liu, Zhaoxia Tian and Zhong Zhao, 9 October 2020, Science. DOI: 10.1126/science.abb7360

Link:
Mystery Solved: How Do Tips of Plants Stay Virus-Free in Face of Intensive Infection? - SciTechDaily

Scientists grow mini-lungs in lab, infect them with coronavirus and watch battle in real time – The Indian Express

Written by Kabir Firaque | New Delhi | October 24, 2020 2:17:37 pm Medical workers check a X-ray photo of a lung of a patient suffering of Covid-19 in the Nouvel Hopital Civil of Strasbourg, eastern France, Thursday, Oct.22, 2020. (AP Photo: Jean-Francois Badias, File)

The novel coronavirus is known to attack primarily the lungs, but how the attack unfolds is still a subject of research. Now, two studies have thrown light on these processes by using the same approach. Scientists have developed lung models in the lab, infected these with SARS-CoV-2, and watched the battle between the lung cells and the virus.

Both papers are published in the journal Cell Stem Press. One study is by South Korean and UK researchers, including from the University of Cambridge; the other is by researchers from Duke University and University of North Carolina.

In both studies, scientists observed how the virus damages the alveoli in the lungs. Alveoli are balloon-like air sacs that take up the oxygen we breathe and release the carbon dioxide we exhale. Damage to alveoli causes pneumonia and acute respiratory distress the leading cause of death in Covid-19.

Both teams developed the model using mini-lungs or lung organoids. The organoids were grown from the stem cells that repair the deepest portions of the lungs where SARS-CoV-2 attacks. These are called AT2 cells. Follow Express Explained on Telegram

The UK and South Korean team reprogramed the AT2 cells back to their earlier stem cell stage. They grew self-organising, alveolar-like 3D structures that mimic the behaviour of key lung tissue. When the 3D models were exposed to SARS-CoV-2, the virus began to replicate rapidly.

In six hours, cells began to produce interferonsproteins that act as warning signals to neighbouring cells. After 48 hours, the cells started fighting back. And after 60 hours from infection, some of the alveolar cells began to disintegrate, leading to cell death and damage to the tissue.

In the other study, led by Duke University cell biologist Purushothama Rao Tata, the team got a single lung cell to multiply into thousands of copies and create a structure that resembles breathing tissues of the human lung. Once infected with the virus, the model showed an inflammatory response.

The team also witnessed the cytokine storm the hyper reaction of immune molecules the lungs launch to fight the infection.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

The Indian Express (P) Ltd

Here is the original post:
Scientists grow mini-lungs in lab, infect them with coronavirus and watch battle in real time - The Indian Express

Platelet Rich Plasma & Stem Cell Alopecia Treatment Market 2020: Reporting and Evaluation of Recent Industry Developments – Eurowire

The report provides study at global and regional level to provide comprehensive value market analysis for the years (2017 & 2018 Historic Years, 2019 Base Year and 2020-2027 Forecast Period). The Platelet Rich Plasma & Stem Cell Alopecia Treatment Market research report is a wide-ranging study of current trends, market growth drivers, and restraints. Each market segment is broadly analyzed at a powdered level by region (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America) to provide thorough information on the global and regional level.

Some of the key players in this market include

Download Sample PDF Brochure of this research study at https://www.theinsightpartners.com/sample/TIPRE00004413/

The global platelet rich plasma & stem cell alopecia treatment market is segmented on the basis of treatment and end user. Based on treatment, the market is segmented as, stem cell therapy and platelet rich plasma therapies. The platelet rich plasma & stem cell alopecia treatment market is categorized based on end user such as, dermatology clinics, hospitals and other end users.

The segmentation in this research study has been finalized post in-depth secondary research and extensive primary research. In addition, the market is also segmented on the basis of technology offered by the leading participants in the industry in order to understand widely used market specific terminologies. Thus, we have incorporated the segments of the research and have finalized the market segmentation.

The Insight Partners Platelet Rich Plasma & Stem Cell Alopecia Treatment Market Research Report Scenario includes:

Order a copy of this research study at https://www.theinsightpartners.com/buy/TIPRE00004413/

The report also covers a detailed chapter of the analysis on COVID-19 impact on this market at global and regional level in our final reports.

This research provides detailed information regarding the major factors influencing the growth of the Platelet Rich Plasma & Stem Cell Alopecia Treatment Market in Global and Regional Level (drivers, restraints, opportunities, and challenges), forecast of the market size, in terms of value, market share by region and segment; regional market positions; segment and country opportunities for growth; New product developments, strengths and weaknesses, brand portfolio; Marketing and distribution strategies; challenges and threats from current competition and prospects; Key company profiles, SWOT, product portfolio and growth strategies.

ABOUT US:

The Insight Partners is a one stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Our research model is very simple. We believe in client servicing and delivering best quality to our customers. Through our research content, we are making sure that our customers get value of their money along with better quality data and analysis.

Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis etc. We provide detailed break-up of segmentation in terms of geography, technology, product and services etc.; which helps our clients to get a deeper analysis on various research topics.

Contact US:

If you have any queries about this report or would like further information, please contact us:

North America: +1 646 491 9876

Asia-Pacific: +91 20 6727 8686

Email: [emailprotected]

Original post:
Platelet Rich Plasma & Stem Cell Alopecia Treatment Market 2020: Reporting and Evaluation of Recent Industry Developments - Eurowire